VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced topline results from the ELEVATE study, a Phase 2 study of AV-101, its NMDA (N-methyl-D-aspartate) receptor glycine site antagonist, as an adjunctive treatment of major depressive disorder (MDD). In this study, the AV-101 treatment arm did not differentiate from placebo on the primary endpoint (change in the Montgomery-Ã…sberg Depression Rating Scale (MADRS-10) total score compared to baseline). As in prior clinical studies, AV-101 was well tolerated, with no psychotomimetic side effects or serious adverse events.
NEW YORK, Oct. 14, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that it will release top-line data from its Phase 2 study of REL-1017 in patients with treatment resistant depression tomorrow, October 15, 2019, before the market opens.
The TGA is working with sponsors of certain inhaled or injected general anaesthetic agents and sedative medicines to update information about the potential risk of deficits in learning and behavioural development in children, which may be associated with repeated or prolonged exposure to these products during late pregnancy or early childhood.
How Ketamine could cure depression
Market Place
Share Share
Share Share
